Sarepta Therapeutics Inc. (SRPT) Insider Trading

Last 12 months

Insiders sold $417k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Director Stephen Mayo sold $123k on Mar 12, 80% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2024.

Net open-market

−$417k

0 buys · 2 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Aug 2024

Aug 16, 2024

Get an email when SRPT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Mar 12	Stephen Mayo Director	SoldNo plan	7,239	$17.02	$123k	80%	Form 4
Dec 16, 2025	Ian Michael Estepan Chief Operating Officer	SoldNo plan	13,187	$22.31	$294k	6.4%	Form 4
Mar 12, 2025	Claude Nicaise Director	SoldNo plan	2,491	$99.64	$248k	8.2%	Form 4
Dec 12, 2024	Hans Lennart Rudolf Wigzell Director	SoldNo plan	10,500	$124.84	$1.31M	31%	Form 4
Dec 5, 2024	Kathryn Jean Boor Director	SoldNo plan	1,636	$125.55	$205k	22%	Form 4

Mar 12No plan
Stephen Mayo
Director · sold 7,239 at $17.02
$123k
80% of stake
Dec 16, 2025No plan
Ian Michael Estepan
Chief Operating Officer · sold 13,187 at $22.31
$294k
6.4% of stake
Mar 12, 2025No plan
Claude Nicaise
Director · sold 2,491 at $99.64
$248k
8.2% of stake
Dec 12, 2024No plan
Hans Lennart Rudolf Wigzell
Director · sold 10,500 at $124.84
$1.31M
31% of stake
Dec 5, 2024No plan
Kathryn Jean Boor
Director · sold 1,636 at $125.55
$205k
22% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SRPT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

ALKSAlkermes plc

RPRXRoyalty Pharma plc

PAHCPhibro Animal Health Corporation

INDVIndivior Pharmaceuticals, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

ACADAcadia Pharmaceuticals Inc.

APLSApellis Pharmaceuticals, Inc.

PBHPrestige Consumer Healthcare Inc.

Spot a number that looks wrong? Check it in SRPT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SRPT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.